Neurogene (NGNE) Retained Earnings (2013 - 2026)
Neurogene (NGNE) reported Retained Earnings of -$383.6 million for Q1 2026, down 34.64% on a YoY basis from -$586.9 million in Q1 2025, and down 8.77% quarter-over-quarter from -$352.6 million in Q4 2025.
Neurogene (NGNE) Retained Earnings (2013 - 2026) Analysis & Trends
Neurogene has reported Retained Earnings for 14 years, with the latest figure at -$383.6 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 34.64% year-over-year to -$383.6 million; the trailing twelve-month figure through Mar 2026 stood at -$383.6 million (down 34.64% YoY), and the FY2025 full-year result was -$352.6 million, down 34.45% from the prior year.
- Retained Earnings for Q1 2026 stood at -$383.6 million, down from -$352.6 million in the prior quarter.
- The five-year high for Retained Earnings was $18000.0 in Q1 2023, with the low at -$471.9 million in Q3 2023.
- Historically, Retained Earnings has averaged -$248.9 million across 5 years, with a median of -$262.3 million in 2024.
- Annual changes were most pronounced in 2023 — Retained Earnings jumped 100.0% — and 2024, when it plunged 1712207.69%.
- Neurogene's Retained Earnings stood at -$150.8 million in 2022, then slipped by 24.08% to -$187.2 million in 2023, then slumped by 40.15% to -$262.3 million in 2024, then slumped by 34.45% to -$352.6 million in 2025, then decreased by 8.77% to -$383.6 million in 2026.
- The last three Retained Earnings figures came in at -$383.6 million (Q1 2026), -$352.6 million (Q4 2025), and -$327.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | -383.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -383.58 Mn |
| Dec 31, 2025 | -352.65 Mn |
| Sep 30, 2025 | -327.91 Mn |
| Jun 30, 2025 | -306.96 Mn |
| Mar 31, 2025 | -284.90 Mn |
| Dec 31, 2024 | -262.30 Mn |
| Sep 30, 2024 | -242.78 Mn |
| Jun 30, 2024 | -222.60 Mn |
| Mar 31, 2024 | -204.10 Mn |
| Dec 31, 2023 | -187.15 Mn |
| Sep 30, 2023 | -471.87 Mn |
| Jun 30, 2023 | -13,000.00 |
| Mar 31, 2023 | 18,000.00 |
| Dec 31, 2022 | -150.84 Mn |
| Sep 30, 2022 | -92,000.00 |
| Jun 30, 2022 | -424.54 Mn |
| Mar 31, 2022 | -408.85 Mn |
| Dec 31, 2021 | -393.50 Mn |
| Sep 30, 2021 | -378.33 Mn |
| Jun 30, 2021 | -362.89 Mn |